



## The alpha prototype of the instrument delivered to Lumito according to plan

**Lumito's development partner TTP has delivered the alpha prototype of what will be Lumito's first product. After delivery, the instrument has successfully undergone internal acceptance testing.**

The ongoing development phase of Lumito's first product includes the development of an alpha prototype, with essential functionality implemented ("work like"), and thereafter a beta prototype, with complete implementation of functionality and design ("work like – look like").

The alpha prototype was delivered according to plan by Lumito's development partner TTP at the end of July. It has now undergone an acceptance test at Lumito's premises, with successful result.

– It is an important step that we are now able to work with the prototype on site to provide input for the further development of the beta prototype, and that we will now be able to demonstrate the functionality here in Lund to prospective customers and partners, says Lumito's CEO, Stefan Nilsson.

For more information contact:

Lumito AB (publ), CEO Stefan Nilsson, telefon +46 767 78 59 05, [sn@lumito.se](mailto:sn@lumito.se)

### **Lumito in brief**

Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito's IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. Lumito has an agreement with TTP plc (The Technology Partnership) in Cambridge, UK, regarding development of instruments and staining reagents. Lumito's share Lumito and warrant Lumito TO1 are traded at the NGM Nordic MTF marketplace.